CLAIMS

1. A solid oral dosage form pharmaceutical for the treatment of dysuria, which comprises, as an active ingredient, an indoline compound having an α_1-adrenoceptor blocking activity and represented by the formula:



prodrug, pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein 85% dissolution time is not more than 60 minutes in a dissolution test according to method 2 (paddle method) of Japanese pharmacopoeia in a condition using water as a test medium and a paddle speed of 50rpm.

2. The pharmaceutical according to claim 1, wherein 85% dissolution time is not more than 60 minutes in a dissolution test according to method 2 (paddle method) of Japanese pharmacopoeia in a condition using the first fluid regulated in a disintegration test of Japanese pharmacopoeia as a test medium and a paddle speed of 50rpm.

3. The pharmaceutical according to claim 1 or 2, wherein 85% dissolution time is not more than 30 minutes.

4. The pharmaceutical according to claim 3, wherein 85%

dissolution time is not more than 15 minutes.

5. The pharmaceutical according to any one of claims 1 to 4, which comprises D-mannitol as a filler.

6. The pharmaceutical according to claim 5, which further comprises a lubricant.

7. The pharmaceutical according to claim 6, wherein the lubricant is magnesium stearate, calcium stearate or talc.

8. The pharmaceutical according to claim 6, wherein the lubricant is magnesium stearate.

9. The pharmaceutical according to claim 8, which further comprises 0.1 to 2 parts of sodium lauryl sulfate based on 1 part of magnesium stearate.

10. The pharmaceutical according to any one of claims 1 to 9, wherein a dosage form is in the form of a capsule or a tablet.

11. The pharmaceutical according to claim 10, wherein the capsule is a light-shielding capsule, or the tablet is coated with a light-shielding coating agent.

12. The pharmaceutical according to claim 11, wherein the light-shielding capsule is a capsule containing titanium oxide.

13. The pharmaceutical according to claim 11, wherein the light-shielding coating agent is a coating agent containing titanium oxide.

14. The pharmaceutical according to any one of claims 1 to 13, which further comprises, as an active ingredient, at least one selected from the group consisting of an α_1-adrenoceptor blocking agent, an anticholinergic agent, an antiinflammatory agent and an antibacterial agent other than an indoline compound of claim 1.

15. A pharmaceutical for the treatment of dysuria, which comprises a pharmaceutical according to any one of claims 1 to 14, in combination with a pharmaceutical comprising, as an active ingredient, at least one selected from the group consisting of an α_1-adrenoceptor blocking agent, an anticholinergic agent, an antiinflammatory agent and an antibacterial agent other than an indoline compound of claim 1.

16. The pharmaceutical according to any one of claims 1 to 15, which is used for the treatment of dysuria.

17. The pharmaceutical according to claim 16, wherein the dysuria is associated with urethra organized blockage, disorders of urination control nerve or urethra functional blockage.

18. The pharmaceutical according to claim 16, wherein the dysuria is associated with prostate hypertrophy, neurogenic bladder or a lower urinary tract disorder.